Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Pituitary Adenoma in Pediatric and Adolescent Populations.

Chen J, Schmidt RE, Dahiya S.

J Neuropathol Exp Neurol. 2019 Apr 26. pii: nlz040. doi: 10.1093/jnen/nlz040. [Epub ahead of print]

PMID:
31115468
2.

The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.

Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr.

J Neurosurg. 2002 Feb;96(2):195-208.

PMID:
11838791
3.

Atypical pituitary adenoma: a clinicopathologic case series.

Rutkowski MJ, Alward RM, Chen R, Wagner J, Jahangiri A, Southwell DG, Kunwar S, Blevins L, Lee H, Aghi MK.

J Neurosurg. 2018 Apr;128(4):1058-1065. doi: 10.3171/2016.12.JNS162126. Epub 2017 Jun 9.

PMID:
28598278
4.

Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.

Del Basso De Caro M, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM, Colao A, Pettinato G, Cappabianca P.

Neurosurg Rev. 2017 Jan;40(1):105-114. doi: 10.1007/s10143-016-0740-9. Epub 2016 May 23.

PMID:
27215912
5.

Atypical pituitary adenomas: incidence, clinical characteristics, and implications.

Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr.

J Neurosurg. 2011 Feb;114(2):336-44. doi: 10.3171/2010.8.JNS10290. Epub 2010 Sep 24.

PMID:
20868211
6.

Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.

Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, de Waure C, Lauriola L, Mangiola A, Anile C, Maira G, De Marinis L, Bianchi A.

Neuroendocrinology. 2015;101(2):143-50. doi: 10.1159/000375448. Epub 2015 Jan 29.

PMID:
25633744
7.

Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification.

Micko AS, Wöhrer A, Wolfsberger S, Knosp E.

J Neurosurg. 2015 Apr;122(4):803-11. doi: 10.3171/2014.12.JNS141083. Epub 2015 Feb 6.

PMID:
25658782
8.

Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence.

Yoshino A, Katayama Y, Fukushima T, Watanabe T, Komine C, Yokoyama T, Kusama K, Moro I.

J Neurooncol. 2003 Jun;63(2):155-62.

PMID:
12825819
9.

Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal.

Tortosa F, Webb SM.

Neurologia. 2016 Mar;31(2):97-105. doi: 10.1016/j.nrl.2015.06.010. Epub 2015 Aug 20. English, Spanish.

10.

Refractory pituitary adenoma: a novel classification for pituitary tumors.

Dai C, Feng M, Liu X, Ma S, Sun B, Bao X, Yao Y, Deng K, Wang Y, Xing B, Lian W, Zhong D, Ma W, Wang R.

Oncotarget. 2016 Dec 13;7(50):83657-83668. doi: 10.18632/oncotarget.13274.

11.

EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway.

Wang J, Liu Q, Gao H, Wan D, Li C, Li Z, Zhang Y.

Tumour Biol. 2017 Jul;39(7):1010428317706203. doi: 10.1177/1010428317706203.

PMID:
28705113
12.

Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.

Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Böcher-Schwarz HG, Hainfellner J, Knosp E.

Acta Neurochir (Wien). 2004 Aug;146(8):831-9. Epub 2004 Jun 14.

PMID:
15254805
13.

Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.

Chen SF, Kasajima A, Yazdani S, Chan MS, Wang L, He YY, Gao HW, Sasano H.

Hum Pathol. 2013 Oct;44(10):2199-203. doi: 10.1016/j.humpath.2013.04.025. Epub 2013 Aug 16.

PMID:
23954140
14.

Recurrences of Pituitary Adenomas or Second De Novo Tumors: Comparisons with First Tumors.

Saeger W, Müller M, Buslei R, Flitsch J, Fahlbusch R, Buchfelder M, Knappe UJ, Crock PA, Lüdecke DK.

World Neurosurg. 2018 Nov;119:e118-e124. doi: 10.1016/j.wneu.2018.07.056. Epub 2018 Jul 17.

PMID:
30026158
15.

Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.

Batista RL, Trarbach EB, Marques MD, Cescato VA, da Silva GO, Herkenhoff CGB, Cunha-Neto MB, Musolino NR.

World Neurosurg. 2018 Dec;120:e241-e246. doi: 10.1016/j.wneu.2018.08.043. Epub 2018 Aug 20.

PMID:
30138730
16.

Radiation therapy in the multimodal treatment approach of pituitary adenoma.

Becker G, Kocher M, Kortmann RD, Paulsen F, Jeremic B, Müller RP, Bamberg M.

Strahlenther Onkol. 2002 Apr;178(4):173-86. Review.

PMID:
12040754
17.

Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up.

Lv L, Yin S, Zhou P, Hu Y, Chen C, Ma W, Jiang Y, Wang Z, Jiang S.

World Neurosurg. 2018 Oct;118:e428-e435. doi: 10.1016/j.wneu.2018.06.210. Epub 2018 Jul 4.

PMID:
29981466
18.

Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas.

Sarkar S, Philip VJ, Cherukuri SK, Chacko AG, Chacko G.

Acta Neurochir (Wien). 2017 Nov;159(11):2179-2186. doi: 10.1007/s00701-017-3223-z. Epub 2017 Jun 1.

PMID:
28573325
19.

Ectopic ACTH-secreting pituitary adenoma of the sphenoid sinus: case report of endoscopic endonasal resection and systematic review of the literature.

Seltzer J, Lucas J, Commins D, Lerner O, Lerner A, Carmichael JD, Zada G.

Neurosurg Focus. 2015 Feb;38(2):E10. doi: 10.3171/2014.10.FOCUS14685. Review.

PMID:
25639312
20.

P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas.

Hentschel SJ, McCutcheon lE, Moore W, Durity FA.

Can J Neurol Sci. 2003 Aug;30(3):215-9.

PMID:
12945944

Supplemental Content

Support Center